The upcoming earnings report for IDXX is scheduled for Monday, May 4th, with a consensus estimate EPS of 3.42.
IDEXX Laboratories, Inc. (IDXX) is currently priced at $568.66, with a price change of -$6.29 (-1.09%) from the previous close. The trading volume is at $186,822, representing a 34.83% increase relative to the average.
The latest quarterly earnings for IDXX were reported on Sunday, February 1st, with a consensus estimate EPS of 2.93.
IDXX shows a positive free cash flow of $322.59 million, with debt repayment of $132.00 million and a net decrease in cash of $28 million.
IDXX generated a revenue of $1 billion, resulting in a net income of $248.19 million. The EPS stands at $3.1, with an EBITDA of $356.22 million.
Key ratios for IDXX include a net profit margin of 22.76%, a return on equity of 15.46%, and a price-to-earnings ratio of 54.58.
IDXX holds $180 million in cash and cash equivalents, with total assets amounting to $3.35 billion and total liabilities of $1.75 billion.
This comprehensive overview provides insights into IDXX's financial performance and upcoming earnings, reflecting a mixed picture of profitability and liquidity.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.